Modality
mRNA
MOA
PD-L1i
Target
IL-23
Pathway
Angiogenesis
MesoAML
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
~Jan 2021
→ ~Apr 2022
Phase 3
~Jul 2022
→ ~Oct 2023
NDA/BLA
Jan 2024
→ Jul 2030
NDA/BLACurrent
NCT07937321
1,210 pts·Meso
2024-01→2030-07·Active
1,210 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-07-184.3y awayPh3 Readout· Meso
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-07-18 · 4.3y away
Meso
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07937321 | NDA/BLA | Meso | Active | 1210 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA |